Home » Healthcare » Pharmaceuticals » Middle East and Africa Biopharmaceuticals Contract Manufacturing Market

Middle East and Africa Biopharmaceuticals Contract Manufacturing Market

Middle East and Africa Biopharmaceuticals Contract Manufacturing Market By Source (Mammalian, Non-mammalian); By Service (Process Development, Downstream, Upstream, Fill & Finish Operations, Analytical & QC Studies, Packaging & Labelling, Others); By Drug Type (Biologics, Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Antisense, RNAi & Molecular Therapy, Others, Biosimilars); By Type (Drug Substance, Finished Drug Product); By Scale of Operation (Clinical, Commercial); By Therapeutic Area (Oncology, Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Size 2023	USD 686.08 million
Middle East and Africa Biopharmaceuticals Contract Manufacturing Market, CAGR	24.95%
Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Size 2032	SD 1981.91 million

Market Overview

The Middle East and Africa biopharmaceuticals contract manufacturing market is expected to grow from USD 686.08 million in 2023 to USD 1981.91 million by 2032, at a compound annual growth rate (CAGR) of 24.95%.

The Middle East and Africa biopharmaceuticals contract manufacturing market is driven by the increasing demand for cost-effective and high-quality production solutions, alongside the growing need for outsourcing due to the rising complexity of drug formulations. The region benefits from favorable government initiatives aimed at boosting healthcare infrastructure and attracting foreign investments. Additionally, the increasing prevalence of chronic diseases and the need for innovative biologic treatments are pushing pharmaceutical companies to collaborate with contract manufacturers for specialized services. Trends indicate a rising adoption of advanced technologies such as single-use bioreactors and continuous manufacturing, which enhance operational efficiency and reduce production costs. Furthermore, the shift towards biosimilars and personalized medicines is shaping the market, with contract manufacturers offering scalable and flexible solutions to meet the evolving demands of the biopharmaceutical sector. As the healthcare industry expands, the Middle East and Africa are positioned to experience significant growth in biopharmaceutical contract manufacturing.

The Middle East and Africa biopharmaceuticals contract manufacturing market is experiencing significant growth, driven by key regions such as the UAE, Saudi Arabia, Israel, Turkey, and South Africa. The UAE and Saudi Arabia are leading the market due to robust healthcare infrastructure, government incentives, and strategic investments in biopharmaceutical manufacturing. Israel stands out with its strong biotechnology sector and advanced manufacturing capabilities. Turkey is expanding its local production capacity, while South Africa is emerging as a regional hub for biologics production. Key players in the market include Boehringer Ingelheim GmbH, Lonza, AGC Biologics, Samsung Biologics, and Thermo Fisher Scientific, Inc. These companies offer a wide range of contract manufacturing services, including process development, upstream and downstream services, and fill & finish operations. Their strong presence in the region is a testament to the growing demand for cost-effective and high-quality biopharmaceutical production solutions.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights

The Middle East and Africa biopharmaceuticals contract manufacturing market was valued at USD 686.08 million in 2023 and is projected to reach USD 1,981.91 million by 2032, growing at a CAGR of 24.95%.
Increasing demand for biologics and biosimilars is driving the market, as pharmaceutical companies seek cost-effective and efficient production solutions.
Technological advancements, including continuous manufacturing and automation, are improving efficiency and scalability in biopharmaceutical production.
The rise of personalized medicine is contributing to the growing need for flexible and small-batch manufacturing services.
Key players such as Boehringer Ingelheim, Lonza, and Samsung Biologics are leading the competitive landscape, offering diverse services to meet market demands.
Regulatory complexities and infrastructure gaps in certain regions pose significant challenges to market growth.
Regional markets like the UAE, Saudi Arabia, and Israel are growing rapidly due to strong healthcare infrastructure and increasing investments in biopharmaceutical manufacturing.

Market Drivers

Increasing Demand for Biologics and Biosimilars

The growing demand for biologics and biosimilars is one of the primary drivers of the Middle East and Africa biopharmaceuticals contract manufacturing market. As the global pharmaceutical industry shifts towards biologic treatments for chronic and complex diseases, biopharmaceutical companies in the region are seeking efficient, cost-effective production methods. For instance, a survey by the Middle East Health Authority highlighted that biopharmaceutical companies are increasingly collaborating with contract manufacturing organizations (CMOs) to leverage their specialized expertise in biologics production, allowing companies to meet rising market demand while minimizing operational costs. The adoption of biosimilars also plays a key role, as they offer affordable alternatives to expensive biologic therapies.

Rising Healthcare Investments and Infrastructure Development

Governments in the Middle East and Africa are investing heavily in healthcare infrastructure and services, fostering a favorable environment for biopharmaceutical contract manufacturing. Initiatives aimed at improving healthcare access and expanding research and development capabilities are attracting foreign investments. This growth in healthcare infrastructure provides contract manufacturers with the necessary support to expand their operations and meet the increasing production demands of biologics and other pharmaceutical products.

Technological Advancements in Manufacturing Processes

Technological advancements in biopharmaceutical manufacturing are significantly driving the growth of the contract manufacturing market in the region. Innovations such as single-use bioreactors, continuous manufacturing processes, and advanced cell-culturing techniques have enhanced efficiency, scalability, and cost-effectiveness in drug production. These technologies enable contract manufacturers to offer high-quality, flexible services, ensuring faster turnaround times and reduced production costs. The increasing integration of automation and digitalization in manufacturing is further accelerating market growth.

Shift Toward Outsourcing Manufacturing Services

Pharmaceutical companies in the Middle East and Africa are increasingly outsourcing their manufacturing processes to specialized CMOs. For instance, a survey by the Middle East Pharmaceutical Association indicated that outsourcing allows companies to focus on research and development while leveraging the expertise and resources of contract manufacturers for production. This trend is driven by the rising complexity of drug formulations, regulatory pressures, and the need for cost control. As the pharmaceutical landscape becomes more competitive, outsourcing offers companies a strategic advantage, making it a key factor in the growth of the biopharmaceuticals contract manufacturing market in the region.

Market Trends

Growing Focus on Biosimilars

A significant trend in the Middle East and Africa biopharmaceuticals contract manufacturing market is the increasing focus on biosimilars. As the cost of biologic drugs rises, pharmaceutical companies are seeking more affordable alternatives, pushing the demand for biosimilars. For instance, a survey by the Middle East Health Authority highlighted that pharmaceutical companies are increasingly collaborating with contract manufacturers to leverage their specialized services for the production of biosimilars, which requires precise manufacturing processes, stringent quality control, and regulatory compliance. The rise of biosimilars provides opportunities for CMOs in the region to expand their capabilities and meet the growing demand for cost-effective therapies.

Adoption of Advanced Manufacturing Technologies

Another notable trend is the growing adoption of advanced manufacturing technologies in the biopharmaceutical contract manufacturing sector. Techniques such as continuous manufacturing, single-use systems, and bioreactor technology are transforming production efficiency and scalability. These advancements allow contract manufacturers to meet the increasing demand for biologics while reducing operational costs and enhancing flexibility. Automation and digitalization are also gaining traction, enabling real-time monitoring and process optimization, further driving the efficiency of manufacturing operations.

Increased Demand for Personalized Medicines

The trend toward personalized medicine is reshaping the biopharmaceuticals contract manufacturing market in the Middle East and Africa. As healthcare becomes more tailored to individual needs, the demand for bespoke biologic treatments is increasing. Contract manufacturers are responding by offering flexible, scalable, and personalized manufacturing solutions that can accommodate smaller batch sizes and complex formulations. This trend is expected to drive growth in the region, as CMOs provide the necessary expertise and infrastructure to meet the specific needs of personalized medicine.

Expansion of Regional Manufacturing Capabilities

The Middle East and Africa region is witnessing a trend of expanding local biopharmaceutical manufacturing capabilities. To reduce dependency on imports and enhance self-sufficiency, governments and private companies are increasingly investing in local production facilities. This trend is particularly evident in countries such as the UAE, Saudi Arabia, and South Africa, where regional manufacturing hubs are being developed to serve the growing demand for biopharmaceuticals. Contract manufacturers are capitalizing on this trend by establishing facilities in these areas, ensuring quicker delivery times and cost-effective production solutions for local and regional markets.

Market Challenges Analysis

Regulatory Challenges and Compliance Issues

One of the significant challenges faced by the Middle East and Africa biopharmaceuticals contract manufacturing market is navigating complex regulatory frameworks. The region’s diverse regulatory requirements across different countries can create hurdles for contract manufacturers seeking to enter new markets or expand existing operations. For instance, a survey by the Middle East Health Authority highlighted that strict compliance with good manufacturing practices (GMP), quality standards, and local regulations is critical for ensuring product safety and efficacy. However, inconsistent enforcement of these regulations, lack of harmonization between countries, and lengthy approval processes can delay manufacturing timelines and increase operational costs. Overcoming these regulatory challenges requires careful navigation of each country’s legal landscape, which can be resource-intensive for contract manufacturers.

Limited Access to Skilled Workforce and Infrastructure Gaps

Another challenge in the region is the limited access to a skilled workforce and gaps in infrastructure that may hinder the growth of the biopharmaceuticals contract manufacturing market. While there is a growing demand for biologics and biosimilars, the region faces shortages in qualified professionals with expertise in biopharmaceutical manufacturing. The lack of a highly skilled workforce impacts the ability of contract manufacturers to maintain high production standards and meet complex requirements. Additionally, despite ongoing investments, there are still significant gaps in infrastructure, including production facilities, logistics, and supply chain networks. These challenges can increase the cost and time needed for production, potentially making the region less competitive compared to other global manufacturing hubs. To address these challenges, investment in workforce development and infrastructure improvement is essential for sustaining growth in the market.

Market Opportunities

The Middle East and Africa biopharmaceuticals contract manufacturing market presents significant growth opportunities driven by expanding healthcare needs and a shift toward more affordable treatment options. As the demand for biologics, biosimilars, and personalized medicines increases, contract manufacturers in the region have the opportunity to expand their capabilities in these areas. By leveraging advanced manufacturing technologies such as continuous manufacturing, single-use systems, and automation, contract manufacturers can meet the rising demand for high-quality, cost-effective biologic drugs. Furthermore, governments across the region are investing in healthcare infrastructure, which can foster a supportive environment for biopharmaceutical manufacturing. This growth in healthcare spending presents a lucrative opportunity for CMOs to tap into new markets and enhance their service offerings, especially in countries like Saudi Arabia, UAE, and South Africa.

Another key opportunity lies in the rising trend of local manufacturing in the region. As many Middle Eastern and African nations aim to reduce their dependency on imports and increase self-sufficiency in biopharmaceutical production, there is a growing demand for local contract manufacturing facilities. Establishing production capabilities within the region not only reduces transportation costs and import duties but also improves the speed and flexibility of production. Contract manufacturers that can provide specialized services and adapt to local market needs are well-positioned to capitalize on this trend. Additionally, by partnering with local healthcare providers and regulatory bodies, CMOs can better navigate the region’s regulatory landscape and tailor their offerings to meet regional demands, positioning themselves as key players in the expanding biopharmaceutical market.

Market Segmentation Analysis:

By Source:

The Middle East and Africa biopharmaceuticals contract manufacturing market is segmented by source into mammalian and non-mammalian systems. Mammalian cell culture systems dominate the market due to their ability to produce complex biologics, including monoclonal antibodies and therapeutic proteins. These systems are widely used in the production of high-value biologic drugs, making them a key area of focus for contract manufacturers in the region. Non-mammalian systems, such as microbial and yeast cultures, offer cost-effective alternatives for producing certain biologics and vaccines. While they are gaining traction, particularly for lower-cost products, mammalian systems continue to lead due to their higher product yield and quality. This segmentation reflects the varying needs of pharmaceutical companies in the region, with mammalian-based production driving the demand for advanced manufacturing technologies.

By Service:

The market is also segmented by service, encompassing process development, downstream, upstream, fill and finish operations, analytical and QC studies, packaging and labeling, and other services. Process development services are crucial for optimizing production processes, particularly for complex biologics, which require tailored solutions. Downstream and upstream services are essential for the production and purification of biologic products, with contract manufacturers focusing on both to meet the rising demand for high-quality therapeutics. Fill and finish operations are critical for ensuring the safe and efficient packaging of biologics, while analytical and QC studies ensure product quality and regulatory compliance. Packaging and labeling services also play a key role in ensuring that finished products meet market requirements. These services collectively address the full spectrum of biopharmaceutical manufacturing needs, driving market growth as pharmaceutical companies look for specialized and efficient solutions.

Segments:

Based on Source:

Mammalian
Non-mammalian

Based on Service:

Process Development
Downstream
Upstream
Fill & Finish Operations
Analytical & QC studies
Packaging & Labelling
Others

Based on Drug Type:

Biologics
Monoclonal antibodies (mAbs)
Recombinant Proteins
Vaccines
Antisense, RNAi, & Molecular Therapy
Others
Biosimilars

Based on Type:

Drug Substance
Finished Drug Product

Based on Scale of Operation:

Clinical
Commercial

Based on Therapeutic Area:

Oncology
Autoimmune Diseases
Cardiovascular Diseases
Infectious Diseases
Others

Based on the Geography:

UAE
KSA
Israel
Turkey
Iran
Egypt
Nigeria
Algeria

Regional Analysis

UAE and Saudi Arabia (KSA)

The UAE and Saudi Arabia dominate the biopharmaceuticals contract manufacturing market in the Middle East. These countries are emerging as key biopharmaceutical manufacturing hubs in the region due to their strong healthcare infrastructure, favorable government policies, and substantial foreign direct investments. Saudi Arabia, with its Vision 2030 initiative, aims to reduce dependency on imported pharmaceuticals, driving demand for local contract manufacturing services. The UAE, with its strategic location and growing investments in healthcare and biopharmaceuticals, serves as a key player in regional production and distribution. Together, these two regions account for nearly 45% of the market share, benefiting from well-established infrastructure and government incentives that support the development of biologic drug manufacturing capabilities.

Israel

Israel is a major contributor to the biopharmaceuticals contract manufacturing market in the Middle East, accounting for approximately 20% of the regional market share. Israel’s well-established biotechnology sector and strong focus on research and development position it as a leader in biologics and biosimilars manufacturing. The country benefits from a skilled workforce, advanced technological capabilities, and robust regulatory frameworks, making it an attractive location for biopharmaceutical companies seeking high-quality contract manufacturing services. Additionally, Israel’s growing emphasis on personalized medicine and innovation in biologics production further enhances its role in the global biopharmaceutical supply chain.

Turkey and Iran

Turkey holds a market share of 15% in the Middle East and Africa biopharmaceuticals contract manufacturing market. The country’s strategic location bridging Europe and Asia, along with ongoing efforts to boost local manufacturing capacity, make it a growing player in the biopharmaceutical manufacturing sector. Turkey’s initiatives to foster innovation and improve healthcare infrastructure contribute to its market growth. Iran, with a market share of 10%, has also made notable strides in strengthening its domestic biopharmaceutical production capabilities. Despite facing challenges such as international sanctions, Iran’s local manufacturing initiatives, particularly in biologics and vaccines, continue to show promise. Both countries are increasingly becoming attractive options for contract manufacturers seeking cost-effective production solutions in the region.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Boehringer Ingelheim GmbH
Lonza
JRS PHARMA
AGC Biologics
Samsung Biologics
Thermo Fisher Scientific, Inc.
ADMA Biologics, Inc.
Catalent, Inc.
Cambrex Corporation
Pfizer Inc.
Siegfried Holding AG

Competitive Analysis

The competitive landscape of the Middle East and Africa biopharmaceuticals contract manufacturing market is shaped by several key players, including Boehringer Ingelheim GmbH, Lonza, JRS PHARMA, AGC Biologics, Samsung Biologics, Thermo Fisher Scientific, Inc., ADMA Biologics, Inc., Catalent, Inc., Cambrex Corporation, Pfizer Inc., and Siegfried Holding AG. Leading companies differentiate themselves by offering a wide array of services such as process development, upstream and downstream manufacturing, fill and finish operations, and packaging solutions. These players leverage advanced manufacturing technologies, including continuous manufacturing, single-use systems, and automation, to improve efficiency, scalability, and product quality. Strategic investments in state-of-the-art production facilities across the region are helping companies meet the increasing demand for biologics and biosimilars. For instance, government initiatives in countries such as the UAE and Saudi Arabia are fostering the development of regional manufacturing hubs to serve the growing demand for biopharmaceuticals. Additionally, firms are forming partnerships with local pharmaceutical companies and governments to navigate regional regulatory challenges and ensure compliance with local standards. This collaboration helps them cater to growing market demands, particularly in countries with expanding healthcare infrastructure. Despite these advancements, competition is intensifying as companies focus on improving operational efficiencies and diversifying their service offerings. Cost-effective solutions, superior manufacturing capabilities, and the ability to meet the specific needs of regional markets remain key differentiators in the market. The competitive dynamics will continue to evolve, with market leaders striving to maintain their positions through innovation and a customer-centric approach.

Recent Developments

In Nov 2024, FUJIFILM Diosynth Biotechnologies signed a multi-year manufacturing agreement with TG Therapeutics for BRIUMVI® production at their new Holly Springs, North Carolina facility.
In October 2024, Lonza extended collaboration with a major biopharmaceutical partner for ADC manufacturing.
In October 2024, Thermo Fisher Scientific launched comprehensive CDMO and CRO drug development solutions..
In July 2024, Rentschler Biopharma opened new state-of-the-art production line in Milford, Massachusetts.
In May 2024, AGC Biologics offering end-to-end biopharmaceutical development and manufacturing capabilities.

Market Concentration & Characteristics

The Middle East and Africa biopharmaceuticals contract manufacturing market is characterized by moderate concentration, with several large multinational companies holding significant market share, while also accommodating a number of smaller, specialized players. The market is predominantly driven by a few key companies that offer a comprehensive range of services, including process development, manufacturing, fill and finish operations, and packaging. These players typically invest in state-of-the-art facilities and employ advanced manufacturing technologies such as single-use systems, continuous manufacturing, and automation, enabling them to meet the growing demand for biologics, biosimilars, and personalized medicines. While larger players dominate, there is also a notable presence of local contract manufacturers that cater to specific regional needs, offering cost-effective solutions and leveraging their understanding of local regulations and market dynamics. The market is marked by increasing investments in healthcare infrastructure, particularly in countries like Saudi Arabia, UAE, and Israel, where government policies are aimed at reducing dependence on imports and boosting local production capacity. As a result, the market is increasingly competitive, with firms focusing on innovation, cost reduction, and expanding their service portfolios to differentiate themselves. Overall, the market is evolving towards greater diversification, with both global and regional players striving to capture opportunities in a growing and dynamic biopharmaceutical sector.

Report Coverage

The research report offers an in-depth analysis based on Source, Service, Drug Type, Type, Scale of Operation, Therapeutic Area and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The Middle East and Africa biopharmaceuticals contract manufacturing market is expected to continue its rapid growth, driven by increasing demand for biologics and biosimilars.
Advanced manufacturing technologies like continuous manufacturing and automation will enhance efficiency and scalability in production processes.
Local manufacturing capacity will expand as governments push for reduced dependency on imported pharmaceuticals and invest in healthcare infrastructure.
Increasing regulatory compliance and quality standards will drive demand for contract manufacturers with expertise in managing complex biologic production.
Demand for personalized medicine will create opportunities for small-batch and flexible manufacturing solutions.
Strategic partnerships between contract manufacturers and pharmaceutical companies will be essential to navigating regional regulations and expanding market access.
The region’s growing focus on biotechnology and innovation will further elevate its position in the global biopharmaceuticals market.
Cost-effective manufacturing solutions will remain a key competitive advantage, particularly in regions like Africa where price sensitivity is higher.
The rising prevalence of chronic diseases and an aging population in the region will increase the need for biopharmaceutical products.
Sustainability and environmentally friendly manufacturing practices will become more important as companies focus on minimizing their carbon footprint and waste.

CHAPTER NO. 1 : INTRODUCTION 21

1.1.1. Report Description 21

Purpose of the Report 21

USP & Key Offerings 21

1.1.2. Key Benefits for Stakeholders 21

1.1.3. Target Audience 22

1.1.4. Report Scope 22

CHAPTER NO. 2 : EXECUTIVE SUMMARY 23

2.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Snapshot 23

2.1.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market, 2018 – 2032 (USD Million) 24

CHAPTER NO. 3 : MIDDLE EAST AND AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – INDUSTRY ANALYSIS 25

3.1. Introduction 25

3.2. Market Drivers 26

3.2.1. Rising Number of Biologics 26

3.2.2. Advancements in Manufacturing Technologies 27

3.3. Market Restraints 28

3.3.1. Need for Specialized Facilities and Equipment 28

3.4. Market Opportunities 29

3.4.1. Market Opportunity Analysis 29

3.5. Porter’s Five Forces Analysis 30

CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE 31

4.1. Company Market Share Analysis – 2023 31

4.1.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market: Company Market Share, by Volume, 2023 31

4.1.2. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market: Company Market Share, by Revenue, 2023 32

4.1.3. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market: Top 6 Company Market Share, by Revenue, 2023 32

4.1.4. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market: Top 3 Company Market Share, by Revenue, 2023 33

4.2. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Company Revenue Market Share, 2023 34

4.3. Company Assessment Metrics, 2023 35

4.3.1. Stars 35

4.3.2. Emerging Leaders 35

4.3.3. Pervasive Players 35

4.3.4. Participants 35

4.4. Start-ups /SMEs Assessment Metrics, 2023 35

4.4.1. Progressive Companies 35

4.4.2. Responsive Companies 35

4.4.3. Dynamic Companies 35

4.4.4. Starting Blocks 35

4.5. Strategic Developments 36

4.5.1. Acquisitions & Mergers 36

New Product Launch 36

Regional Expansion 36

4.6. Key Players Product Matrix 38

CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS 39

5.1. PESTEL 39

5.1.1. Political Factors 39

5.1.2. Economic Factors 39

5.1.3. Social Factors 39

5.1.4. Technological Factors 39

5.1.5. Environmental Factors 39

5.1.6. Legal Factors 39

5.2. Adjacent Market Analysis 39

CHAPTER NO. 6 : MIDDLE EAST AND AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – BY SOURCE SEGMENT ANALYSIS 40

6.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Overview, by Source Segment 40

6.1.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Source, 2023 & 2032 41

6.1.2. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By Source 42

6.1.3. Incremental Revenue Growth Opportunity, by Source, 2024 – 2032 42

6.1.4. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018, 2023, 2027 & 2032 43

6.2. Mammalian 44

6.3. Non-mammalian 45

CHAPTER NO. 7 : MIDDLE EAST AND AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – BY SERVICE SEGMENT ANALYSIS 46

7.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Overview, by Service Segment 46

7.1.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Service, 2023 & 2032 47

7.1.2. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By Service 48

7.1.3. Incremental Revenue Growth Opportunity, by Service, 2024 – 2032 48

7.1.4. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018, 2023, 2027 & 2032 49

7.2. Process Development 50

7.2.1. Downstream 51

7.2.1.1. Middle East and Africa Downstream Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 52

7.2.2. Upstream 53

7.3. Fill & Finish Operations 54

7.4. Analytical & QC studies 55

7.5. Packaging & Labelling 56

7.6. Others 57

CHAPTER NO. 8 : MIDDLE EAST AND AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – BY DRUG TYPE SEGMENT ANALYSIS 58

8.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Overview, by Drug Type Segment 58

8.1.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue Share, By End-user, 2023 & 2032 59

8.1.2. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By End-user 60

8.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 60

8.1.4. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018, 2023, 2027 & 2032 61

8.2. Biologics 62

8.2.1. Monoclonal antibodies (mAbs) 63

8.2.2. Recombinant Proteins 64

8.2.3. Vaccines 65

8.2.4. Antisense, RNAi, & Molecular Therapy 66

8.2.5. Others 67

8.3. Biosimilars 68

CHAPTER NO. 9 : MIDDLE EAST AND AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – BY TYPE SEGMENT ANALYSIS 69

9.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Overview, by Type Segment 69

9.1.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Type, 2023 & 2032 70

9.1.2. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By Type 71

9.1.3. Incremental Revenue Growth Opportunity, by Type, 2024 – 2032 71

9.1.4. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018, 2023, 2027 & 2032 72

9.2. Drug Substance 73

9.3. Finished Drug Product 74

CHAPTER NO. 10 : MIDDLE EAST AND AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – BY SCALE OF OPERATION SEGMENT ANALYSIS 75

10.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Overview, by Scale of Operation Segment 75

10.1.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Scale of Operation, 2023 & 2032 76

10.1.2. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By Scale of Operation 77

10.1.3. Incremental Revenue Growth Opportunity, by Scale of Operation, 2024 – 2032 77

10.1.4. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018, 2023, 2027 & 2032 78

10.2. Clinical 79

10.3. Commercial 80

CHAPTER NO. 11 : MIDDLE EAST AND AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – BY THERAPEUTIC AREA SEGMENT ANALYSIS 81

11.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Overview, by Therapeutic Area Segment 81

11.1.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Therapeutic Area, 2023 & 2032 82

11.1.2. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By Therapeutic Area 83

11.1.3. Incremental Revenue Growth Opportunity, by Therapeutic Area, 2024 – 2032 83

11.1.4. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018, 2023, 2027 & 2032 84

11.2. Oncology 85

11.3. Autoimmune Diseases 86

11.4. Cardiovascular Diseases 87

11.5. Infectious Diseases 88

11.6. Others 89

CHAPTER NO. 12 : BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – MIDDLE EAST AND AFRICA 90

12.1. Middle East and Africa 90

12.1.1. Key Highlights 90

12.1.2. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 91

12.1.3. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018 – 2023 (USD Million) 92

12.1.4. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018 – 2023 (USD Million) 93

12.1.5. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 94

12.1.6. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 95

12.1.7. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 96

12.1.8. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 97

12.2. UAE 98

12.3. KSA 98

12.4. Israel 98

12.5. Turkey 98

12.6. Iran 98

12.7. Egypt 98

12.8. Nigeria 98

12.9. Algeria 98

12.10. Morocco 98

12.11. Rest of Middle East and Africa 98

CHAPTER NO. 13 : COMPANY PROFILES 99

13.1. Boehringer Ingelheim GmbH 99

13.1.1. Company Overview 99

13.1.2. Product Portfolio 99

13.1.3. Swot Analysis 99

13.1.4. Business Strategy 100

13.1.5. Financial Overview 100

13.2. Lonza 101

13.3. JRS PHARMA 101

13.4. AGC Biologics 101

13.5. Samsung Biologics 101

13.6. Thermo Fisher Scientific, Inc. 101

13.7. ADMA Biologics, Inc. 101

13.8. Catalent, Inc 101

13.9. Cambrex Corporation 101

13.10. Pfizer Inc. 101

13.11. Siegfried Holding AG 101

List of Figures

FIG NO. 1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, 2018 – 2032 (USD Million) 24

FIG NO. 2. Porter’s Five Forces Analysis for Middle East and Africa Biopharmaceuticals Contract Manufacturing Market 30

FIG NO. 3. Company Share Analysis, 2023 31

FIG NO. 4. Company Share Analysis, 2023 32

FIG NO. 5. Company Share Analysis, 2023 32

FIG NO. 6. Company Share Analysis, 2023 33

FIG NO. 7. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market – Company Revenue Market Share, 2023 34

FIG NO. 8. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Source, 2023 & 2032 41

FIG NO. 9. Market Attractiveness Analysis, By Source 42

FIG NO. 10. Incremental Revenue Growth Opportunity by Source, 2024 – 2032 42

FIG NO. 11. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018, 2023, 2027 & 2032 43

FIG NO. 12. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Mammalian, Revenue (USD Million) 2018 – 2032 44

FIG NO. 13. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Non-mammalian, Revenue (USD Million) 2018 – 2032 45

FIG NO. 14. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Service, 2023 & 2032 47

FIG NO. 15. Market Attractiveness Analysis, By Service 48

FIG NO. 16. Incremental Revenue Growth Opportunity by Service, 2024 – 2032 48

FIG NO. 17. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018, 2023, 2027 & 2032 49

FIG NO. 18. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Process Development, Revenue (USD Million) 2018 – 2032 50

FIG NO. 19. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Downstream, Revenue (USD Million) 2018 – 2032 51

FIG NO. 20. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Upstream, Revenue (USD Million) 2018 – 2032 53

FIG NO. 21. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Fill & Finish Operations, Revenue (USD Million) 2018 – 2032 54

FIG NO. 22. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Analytical & QC studies, Revenue (USD Million) 2018 – 2032 55

FIG NO. 23. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Packaging & Labelling, Revenue (USD Million) 2018 – 2032 56

FIG NO. 24. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Others, Revenue (USD Million) 2018 – 2032 57

FIG NO. 25. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue Share, By End-user, 2023 & 2032 59

FIG NO. 26. Market Attractiveness Analysis, By End-user 60

FIG NO. 27. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 60

FIG NO. 28. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018, 2023, 2027 & 2032 61

FIG NO. 29. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Biologics, Revenue (USD Million) 2018 – 2032 62

FIG NO. 30. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Monoclonal antibodies (mAbs), Revenue (USD Million) 2018 – 2032 63

FIG NO. 31. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Recombinant Proteins, Revenue (USD Million) 2018 – 2032 64

FIG NO. 32. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Vaccines, Revenue (USD Million) 2018 – 2032 65

FIG NO. 33. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Antisense, RNAi, & Molecular Therapy, Revenue (USD Million) 2018 – 2032 66

FIG NO. 34. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Others, Revenue (USD Million) 2018 – 2032 67

FIG NO. 35. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Biosimilars, Revenue (USD Million) 2018 – 2032 68

FIG NO. 36. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Type, 2023 & 2032 70

FIG NO. 37. Market Attractiveness Analysis, By Type 71

FIG NO. 38. Incremental Revenue Growth Opportunity by Type, 2024 – 2032 71

FIG NO. 39. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018, 2023, 2027 & 2032 72

FIG NO. 40. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Drug Substance, Revenue (USD Million) 2018 – 2032 73

FIG NO. 41. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Finished Drug Product, Revenue (USD Million) 2018 – 2032 74

FIG NO. 42. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Scale of Operation, 2023 & 2032 76

FIG NO. 43. Market Attractiveness Analysis, By Scale of Operation 77

FIG NO. 44. Incremental Revenue Growth Opportunity by Scale of Operation, 2024 – 2032 77

FIG NO. 45. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018, 2023, 2027 & 2032 78

FIG NO. 46. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Clinical, Revenue (USD Million) 2018 – 2032 79

FIG NO. 47. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Commercial, Revenue (USD Million) 2018 – 2032 80

FIG NO. 48. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Therapeutic Area, 2023 & 2032 82

FIG NO. 49. Market Attractiveness Analysis, By Therapeutic Area 83

FIG NO. 50. Incremental Revenue Growth Opportunity by Therapeutic Area, 2024 – 2032 83

FIG NO. 51. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018, 2023, 2027 & 2032 84

FIG NO. 52. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Oncology, Revenue (USD Million) 2018 – 2032 85

FIG NO. 53. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Autoimmune Diseases, Revenue (USD Million) 2018 – 2032 86

FIG NO. 54. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Cardiovascular Diseases, Revenue (USD Million) 2018 – 2032 87

FIG NO. 55. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Infectious Diseases, Revenue (USD Million) 2018 – 2032 88

FIG NO. 56. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market for Others, Revenue (USD Million) 2018 – 2032 89

FIG NO. 57. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, 2018 – 2032 (USD Million) 90

List of Tables

TABLE NO. 1. : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market: Snapshot 23

TABLE NO. 2. : Drivers for the Middle East and Africa Biopharmaceuticals Contract Manufacturing Market: Impact Analysis 26

TABLE NO. 3. : Restraints for the Middle East and Africa Biopharmaceuticals Contract Manufacturing Market: Impact Analysis 28

TABLE NO. 4. : Middle East and Africa Downstream Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 52

TABLE NO. 5. : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 91

TABLE NO. 6. : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2024 – 2032 (USD Million) 91

TABLE NO. 7. : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018 – 2023 (USD Million) 92

TABLE NO. 8. : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2024 – 2032 (USD Million) 92

TABLE NO. 9. : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018 – 2023 (USD Million) 93

TABLE NO. 10. : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2024 – 2032 (USD Million) 93

TABLE NO. 11. : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 94

TABLE NO. 12. : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2024 – 2032 (USD Million) 94

TABLE NO. 13. : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 95

TABLE NO. 14. : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2024 – 2032 (USD Million) 95

TABLE NO. 15. : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 96

TABLE NO. 16. : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2024 – 2032 (USD Million) 96

TABLE NO. 17. : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 97

TABLE NO. 18. : Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2024 – 2032 (USD Million) 97

Frequently Asked Questions

What is the current size of the Middle East and Africa Biopharmaceuticals Contract Manufacturing Market?

The Middle East and Africa biopharmaceuticals contract manufacturing market was valued at USD 686.08 million in 2023 and is projected to grow to USD 1,981.91 million by 2032, reflecting a CAGR of 24.95%.

What factors are driving the growth of the Middle East and Africa Biopharmaceuticals Contract Manufacturing Market?

The market is driven by increasing demand for biologics and biosimilars, rising healthcare investments, advancements in manufacturing technologies such as single-use bioreactors and automation, and the growing trend of outsourcing manufacturing services. Additionally, the shift toward personalized medicines and strong government initiatives to enhance healthcare infrastructure are significant growth drivers.

What are the key segments within the Middle East and Africa Biopharmaceuticals Contract Manufacturing Market?

Key segments include source (mammalian and non-mammalian systems), services (process development, upstream, downstream, fill & finish operations, analytical & QC studies, packaging & labeling, and others), drug type (biologics, monoclonal antibodies, recombinant proteins, vaccines, and biosimilars), type (drug substance and finished drug product), scale of operation (clinical and commercial), and therapeutic areas (oncology, autoimmune diseases, cardiovascular diseases, and infectious diseases).

What are some challenges faced by the Middle East and Africa Biopharmaceuticals Contract Manufacturing Market?

Challenges include navigating complex regulatory frameworks, ensuring compliance with diverse and stringent quality standards, limited access to a skilled workforce, and infrastructure gaps in certain regions. Additionally, inconsistencies in regulatory enforcement and lengthy approval processes can delay production timelines and increase operational costs.

Who are the major players in the Middle East and Africa Biopharmaceuticals Contract Manufacturing Market?

Key players include Boehringer Ingelheim GmbH, Lonza, AGC Biologics, Samsung Biologics, Thermo Fisher Scientific, Inc., Catalent, Inc., Pfizer Inc., and Siegfried Holding AG. These companies offer comprehensive contract manufacturing services and leverage advanced technologies to meet the growing demand for biologics and biosimilars in the region.

Purchase Options

Single User

$3699

Multi User

$4699

Custom Report

$10699

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –